Anti-Rheumatic Drugs - Bahrain | Statista Market Forecast

The Anti-Rheumatic Drugs market in Bahrain is anticipated to witness a significant growth in revenue, with projections indicating that it will reach a value of US$3.99m in 2024.
Moreover, the market is expected to display a steady annual growth rate (CAGR 2024-2029) of 0.76%, leading to a market volume of US$4.14m by 2029.
When compared globally, it is noteworthy that United States is projected to generate the highest revenue in this market, amounting to US$34.70bn in 2024.
Bahrain's anti-rheumatic drug market is witnessing an increasing demand for biologic medications due to their effectiveness in managing inflammatory diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Bahrain has been steadily growing over the past few years.

Customer preferences: There is a growing preference for biologic drugs among patients in Bahrain. Biologic drugs are known to be more effective in treating rheumatoid arthritis, which is the most common type of arthritis in the country. Patients are also becoming more aware of the side effects of traditional disease-modifying antirheumatic drugs (DMARDs) and are opting for biologics instead.

Trends in the market: The Anti-Rheumatic Drugs market in Bahrain is expected to grow in the coming years due to the increasing prevalence of rheumatoid arthritis in the country. The market is also expected to benefit from the introduction of new biologic drugs, which are more effective in treating the disease. In addition, the government is investing in healthcare infrastructure, which will improve access to healthcare services, including rheumatology services.

Local special circumstances: Bahrain has a high prevalence of rheumatoid arthritis, with around 1% of the population affected by the disease. This is partly due to the high prevalence of consanguineous marriages in the country, which increases the risk of genetic disorders. In addition, the hot and humid climate in Bahrain can exacerbate symptoms of rheumatoid arthritis.

Underlying macroeconomic factors: Bahrain has a small but growing economy, with a focus on the service sector. The government is investing in healthcare infrastructure to improve access to healthcare services, which will benefit the Anti-Rheumatic Drugs market. However, the country is facing economic challenges due to low oil prices and the COVID-19 pandemic, which could impact the growth of the market in the short term.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.